These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 27306072)

  • 1. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
    Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
    Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
    Kopylov U; Afif W; Cohen A; Bitton A; Wild G; Bessissow T; Wyse J; Al-Taweel T; Szilagyi A; Seidman E
    J Crohns Colitis; 2014 Nov; 8(11):1516-22. PubMed ID: 24996483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Chapuis-Biron C; Kirchgesner J; Pariente B; Bouhnik Y; Amiot A; Viennot S; Serrero M; Fumery M; Allez M; Siproudhis L; Buisson A; Pineton de Chambrun G; Abitbol V; Nancey S; Caillo L; Plastaras L; Savoye G; Chanteloup E; Simon M; Dib N; Rajca S; Amil M; Parmentier AL; Peyrin-Biroulet L; Vuitton L;
    Am J Gastroenterol; 2020 Nov; 115(11):1812-1820. PubMed ID: 33156100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.
    Godoy Brewer GM; Salem G; Afzal MA; Limketkai BN; Haq Z; Tajamal M; Melia J; Lazarev M; Selaru FM; Parian AM
    BMJ Open Gastroenterol; 2021 Dec; 8(1):. PubMed ID: 34920992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
    J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Serrero M; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):588-595. PubMed ID: 29315694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
    Castaño-Milla C; Chaparro M; Saro C; Barreiro-de Acosta M; García-Albert AM; Bujanda L; Martín-Arranz MD; Carpio D; Muñoz F; Manceñido N; García-Planella E; Piqueras M; Calvet X; Cabriada JL; Botella B; Bermejo F; Gisbert JP
    J Clin Gastroenterol; 2015 Jan; 49(1):34-40. PubMed ID: 25485513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
    Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
    Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
    Fortea-Ormaechea JI; González-Lama Y; Casis B; Chaparro M; López Serrano P; Van Domselaar M; Bermejo F; Pajares R; Ponferrada A; Vera MI; Martínez Montiel P; Gisbert JP; Pérez-Calle JL; López San Román A; Abreu L; Menchén LA; Marín-Jiménez I
    Gastroenterol Hepatol; 2011; 34(7):443-8. PubMed ID: 21724297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab.
    Zhdanava M; Kachroo S; Boonmak P; Burbage S; Shah A; Lefebvre P; Kerner C; Pilon D
    Adv Ther; 2024 Oct; 41(10):3922-3933. PubMed ID: 39162983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.